Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HER2-positive Breast Cancer: early-phase trial registry
28 of 59 indexed HER2-positive Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #241 of 28,707 conditions by registered trial count.
59 US clinical trials · 28 currently recruiting · #241 of 28,707 conditions by registered trial count
HER2-positive Breast Cancer: 59 US clinical trials tracked, 28 recruiting.
HER2-positive Breast Cancer is the subject of 59 registered US clinical trials on ClinicalTrials.gov, 28 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 46 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 7 of these trials.
Enrollment posture brief
Registry condition her2-positive-breast-cancer
OPEN 28 | RECR 47% | LATE 4 | EARLY 46 | RANK #241 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Metastatic Lung Non-Small Cell Carcinoma (48% recruiting · 40 trials)
HER2-positive Breast Cancer lists 28 open slots (47% of 59 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HER2-positive Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HER2-positive Breast Cancer is recruiting above its size-band peers.
28 of 59 indexed trials (47.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of HER2-positive Breast Cancer trials is spread across many organizations.
H. Lee Moffitt Cancer Center and Research Institute accounts for 7 of 59 trials (11.9%). 38 distinct sponsors appear on at least one study for this condition label.
-
Typical HER2-positive Breast Cancer enrolment sits around 63 participants.
Median target enrolment is 63 among the 59 trials that report a genuine target (sentinel values excluded). 33 of those (55.9%) plan for fewer than 100 participants.
-
HER2-positive Breast Cancer research is mostly interventional.
55 interventional and 4 observational studies make up this index (93.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
59 total, page 2 of 2
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
Washington University School of Medicine
NCT06844669
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
Seagen
NCT02614794
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Pieris Pharmaceuticals
NCT03650348
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
Bavarian Nordic
NCT04246671
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT00006228
Cardiac Safety Study in Patients With HER2 + Breast Cancer
Medstar Health Research Institute
NCT01904903
Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
University of Washington
NCT00331552
Strain Imaging in Breast Cancer Patients Receiving Trastuzumab
University of Florida
NCT02080390
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
University of Washington
NCT00791037
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 28 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on HER2-positive Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HER2-positive Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HER2-positive Breast Cancer page
59 registered trials, 28 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 28 HER2-positive Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- H. Lee Moffitt Cancer Center and Research Institute sponsors the most HER2-positive Breast Cancer trials on record, review their full trial history before evaluating a specific study. See H. Lee Moffitt Cancer Center and Research Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HER2-positive Breast Cancer condition card totals 59 registered trials; most-linked intervention Trastuzumab; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.